Compass Associates
Multi-award-winning recruitment consultancy dedicated to the independent Health, Social Care and Children's Services sectors.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).